“…Moreover, Lenz and colleagues (2014) have shown that montelukast not only has anticonvulsant effect but also protects against BBB disruption and leukocyte infiltration in a cannula-lesioned cortical area, suggesting that montelukast also decreases neuroinflammation and/or exposure to blood-borne elements [15]. It is well known that areas of focal hyperexcitability can develop in the brain after trauma, infection, ischemia, and excitotoxicity, probably due to neuroinflammation and/or exposure to blood-borne elements [43][44][45][46][47][48][49]. Furthermore, pranlukast treatment protects against global cerebral ischemia in rats and inhibits the expression of NMDA-NR2A receptor [50,51].…”